COMMUNIQUÉS West-GlobeNewswire

Inotiv, Inc. to Report Fiscal 2024 First Quarter Financial Results and Host Conference Call on Wednesday, February 7, 2024

29/01/2024 - 22:05

WEST LAFAYETTE, Ind., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

29/01/2024 - 22:05

REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024

29/01/2024 - 22:05

SEATTLE, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical [...]

eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

29/01/2024 - 22:05

SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation regulator inhibitors (“ [...]

Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference

29/01/2024 - 22:05

RADNOR, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD [...]

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

29/01/2024 - 22:01

NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]

Range Impact Announces Former Ohio Congressman Zack Space and Former Ohio Senator Jay Hottinger Have Joined the Company as Strategic Advisors

29/01/2024 - 22:00

CLEVELAND, OHIO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public company dedicated to improving the health and wellness of people and the planet through a novel and innovative [...]

Doheny Eye Institute Research Breakthrough: An Inherited Mutation Blinds Young Adult Males By Disturbing Mitochondrial Quantum Electron Tunneling

29/01/2024 - 18:05

Doheny Eye Institute scientists in collaboration with UCLA Chemists show how a single gene mutation in an enzyme complex known to produce the energy required by cells causes a sudden, blinding disease PASADENA, Calif., [...]

MatrixCare Forges Strategic Partnership with Tranzion, a Subsidiary of NHC, to Expand EHR Services for Senior Living Medical Providers

29/01/2024 - 16:56

BLOOMINGTON, Minn., Jan. 29, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a global technology leader in the post-acute space, is proud to announce its strategic partnership with Tranzion, a newly established subsidiary of NHC ( [...]

Alberta Cancer Foundation announces matching gift campaign with goal of raising $400,000 in support of Patient Financial Assistance Program

29/01/2024 - 16:00

This World Cancer Day, donations to Alberta Cancer Foundation make double the impact, helping thousands of Albertans facing cancer make ends meet EDMONTON, Alberta, Jan. 29, 2024 (GLOBE NEWSWIRE) -- February 4, 2024 [...]

Accelus Introduces LineSider Modular-Cortical System for Posterior Fixation

29/01/2024 - 16:00

Continued expansion of LineSider Spinal System portfolio offers surgeons increased visibility and versatility PALM BEACH GARDENS, Fla., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Accelus , a privately held medical technology [...]

Trading by management and close relations of management

29/01/2024 - 15:59

January 29, 2024 Company announcement No. 04 Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse [...]

Spectral Submits Application for UKCA Mark Classification

29/01/2024 - 15:33

DALLAS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (NASD: MDAI; MDAIW) (“Spectral AI” or the “Company ”) , an artificial intelligence (AI) company focused on medical [...]

Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib

29/01/2024 - 15:05

Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD medications BOSTON and [...]

LTC ACO Continues Growth With Five Additional Provider Partners for Performance Year 2024

29/01/2024 - 14:48

New participants to transition to value-based care, improving quality and cost performance KENNETT SQUARE, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- LTC ACO , the first and only Accountable Care Organization (ACO) in the U [...]

Earth Science Tech, Inc., Announces $5 Million Common Stock Repurchase Program

29/01/2024 - 14:45

Miami, FL, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or “Company”), a holding entity currently focused on the health and wellness industry, today announces that its Board of [...]

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

29/01/2024 - 14:30

-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed to Provide Coverage for Approximately 95% of IPD Circulating in [...]

First Patient Dosed with LIXTE’s LB-100 and GSK’s Immunotherapy Dostarlimab-gxly in Ovarian Clear Cell Carcinoma Trial

29/01/2024 - 14:30

PASADENA, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT and LIXTW ) (“LIXTE” or the “Company”), today announced the dosing of the first patient in a Phase 1b/2 clinical trial to [...]

Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer

29/01/2024 - 14:30

SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular [...]